Abstract:Enterovirus 71 (EV-A71) is one of the predominant etiological agents of hand, foot and mouth disease (HMFD), which can cause severe central nervous system infections in young children. There is no clinically approved vaccine or antiviral agent against HFMD. The SP40 peptide, derived from the VP1 capsid of EV-A71, was reported to be a promising antiviral peptide that targeted the host receptor(s) involved in viral attachment or entry. So far, the mechanism of action of SP40 peptide is unknown. In this study, interactions between ten reported cell receptors of EV-A71 and the antiviral SP40 peptide were evaluated through molecular docking simulations, followed by in vitro receptor blocking with specific antibodies. The preferable binding region of each receptor to SP40 was predicted by global docking using HPEPDOCK and the cell receptor-SP40 peptide complexes were refined using FlexPepDock. Local molecular docking using GOLD (Genetic Optimization for Ligand Docking) showed that the SP40 peptide had the highest binding score to nucleolin followed by annexin A2, SCARB2 and human tryptophanyl-tRNA synthetase. The average GoldScore for 5 top-scoring models of human cyclophilin, fibronectin, human galectin, DC-SIGN and vimentin were almost similar. Analysis of the nucleolin-SP40 peptide complex showed that SP40 peptide binds to the RNA binding domains (RBDs) of nucleolin. Furthermore, receptor blocking by specific monoclonal antibody was performed for seven cell receptors of EV-A71 and the results showed that the blocking of nucleolin by anti-nucleolin alone conferred a 93% reduction in viral infectivity. Maximum viral inhibition (99.5%) occurred when SCARB2 was concurrently blocked with anti-SCARB2 and the SP40 peptide. This is the first report to reveal the mechanism of action of SP40 peptide in silico through molecular docking analysis. This study provides information on the possible binding site of SP40 peptide to EV-A71 cellular receptors. Such information could be useful to further validate the interaction of the SP40 peptide with nucleolin by site-directed mutagenesis of the nucleolin binding site.

Cathelicidin peptide analogues inhibit EV71 infection through blocking viral entry and uncoating

Cathelicidin antimicrobial peptides suppress EV71 infection via regulating antiviral response and inhibiting viral binding

Antiviral Activities of Peptide-Based Covalent Inhibitors of the Enterovirus 71 3c Protease

Inhibition of Enterovirus 71 Replication by an Α-Hydroxy-nitrile Derivative NK-1.9k

Characterization of Three Small Molecule Inhibitors of Enterovirus 71 Identified from Screening of a Library of Natural Products

Peptidyl Aldehyde NK-1.8k Suppresses Enterovirus 71 and Enterovirus 68 Infection by Targeting Protease 3C.

In Vitro and in Vivo Protection Against Enterovirus 71 by an Antisense Phosphorothioate Oligonucleotide

A Novel Peptide from VP1 of EV-D68 Exhibits Broad-Spectrum Antiviral Activity Against Human Enteroviruses

Design, Synthesis and Antiviral Activity of Novel EV71 3C Protease Inhibitors

Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD

New Potent EV-A71 Antivirals Targeting Capsid.

Enterovirus A71 antivirals: Past, present, and future

Scorpion Venom Antimicrobial Peptide Derivative BmKn2-T5 Inhibits Enterovirus 71 in the Early Stages of the Viral Life Cycle In Vitro

Identification of a novel binding inhibitor that blocks the interaction between hSCARB2 and VP1 of enterovirus 71

Molecular Docking of SP40 Peptide towards Cellular Receptors for Enterovirus 71 (EV-A71)

Inhibition of enterovirus 71 infection by polysaccharides extracted from Picochlorum sp. 122 via the AKT and ATM/ATR signaling pathways

Lycorine Derivative LY-55 Inhibits EV71 and CVA16 Replication Through Downregulating Autophagy

Identification of Dibucaine Derivatives As Novel Potent Enterovirus 2C Helicase Inhibitors: in Vitro, in Vivo, and Combination Therapy Study

An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation

Antiviral effects and mechanisms against EV71 of the novel 2-benzoxyl-phenylpyridine derivatives

Antiviral drugs (synthetic small molecule inhibitors and nature drugs) against EV71 in enteroviruses: Advances and Perspectives